Estefania Rojo-Bustamante

Dr. Estefania Rojo-Bustamante

Universidad de Manizales
orcid

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2017 in Neuropharmacology
Verified
Journal Article
Closed access
MCMarta Celorrio
Marta Celorrio
EREstefania Rojo-Bustamante
Estefania Rojo-Bustamante
DFDiana Fernández-Suárez
Diana Fernández-Suárez
ESElena Sáez
Elena Sáez
AMAnder Estella-Hermoso de Mendoza
Ander Estella-Hermoso de Mendoza
MAMaria S Aymerich
Maria S Aymerich

1 October 2016 in Brain, Behavior, and Immunity
Verified
Journal Article
Closed access
MCMarta Celorrio
Marta Celorrio
DFDiana Fernández-Suárez
Diana Fernández-Suárez
EREstefania Rojo-Bustamante
Estefania Rojo-Bustamante
Víctor Echeverry-AlzateVíctor Echeverry-Alzate
Víctor Echeverry-Alzate
Maria Javier RamirezMaria Javier Ramirez
Maria Javier Ramirez
MAMaria S Aymerich
Maria S Aymerich

1 February 2017 in Neuropharmacology
Verified
Journal Article
Closed access
DEDaniela Elgueta
Daniela Elgueta
MAMaria S Aymerich
Maria S Aymerich
FCFrancisco Contreras
Francisco Contreras
AMAndro Montoya
Andro Montoya
MCMarta Celorrio
Marta Celorrio
Rodrigo PachecoRodrigo Pacheco
Rodrigo Pacheco

15 May 2015 in Molecular Neurobiology
Verified
Journal Article
Closed access
PDF file
MAMaria S Aymerich
Maria S Aymerich
EREstefania Rojo-Bustamante
Estefania Rojo-Bustamante
CMCarmen Molina
Carmen Molina
MCMarta Celorrio
Marta Celorrio
JSJuan A. Sánchez-Arias
Juan A. Sánchez-Arias
Rafael FrancoRafael Franco
Rafael Franco

1 October 2018 in Neurobiology of Disease
Verified
Journal Article
Closed access
EREstefania Rojo-Bustamante
Estefania Rojo-Bustamante
MAMiguel A Abellanas
Miguel A Abellanas
PCPedro Clavero
Pedro Clavero
MTMarie-Laure Thiolat
Marie-Laure Thiolat
QLQin Li
Qin Li
MAMaria S Aymerich
Maria S Aymerich

18 August 2020 in Biomolecules
Verified
Journal Article
Open access
PDF file
EREstefania Rojo-Bustamante
Estefania Rojo-Bustamante
IÍIgnacio Íñigo-Marco
Ignacio Íñigo-Marco
MAMiguel A Abellanas
Miguel A Abellanas
RVRodrigo Vinueza-Gavilanes
Rodrigo Vinueza-Gavilanes
ABAna Baltanás
Ana Baltanás
MAMaria S Aymerich
Maria S Aymerich
Monoacylglycerol lipase inhibition (MAGL) has emerged as an interesting therapeutic target for neurodegenerative disease treatment due to its ability to modulate the endocannabinoid system and to prevent the production of proinflammatory mediators. To obtain a beneficial response, it is necessary to understand how this inhibition affects the neuron–glia crosstalk and neuron viability. In this study, the effect of MAGL inhibition by KML29 was evaluated in two types of rat cortical primary cultures; mixed cultures, including neuron and glial cells, and neuron-enriched cultures. The risk of neuronal death was estimated by longitudinal survival analysis. The spontaneous neuronal risk of death in culture was higher in the absence of glial cells, a process that was enhanced by KML29 addition. In contrast, neuronal survival was not compromised by MAGL inhibition in the presence of glial cells. Blockade of cannabinoid type 2 (CB2) receptors expressed mainly by microglial cells did not affect the spontaneous neuronal death risk but decreased neuronal survival when KML29 was added. Modulation of cannabinoid type 1 (CB1) receptors did not affect neuronal survival. Our results show that neuron–glia interactions are essential for neuronal survival. CB2 receptors play a key role in these protective interactions when neurons are exposed to toxic conditions.